{"nctId":"NCT00179621","briefTitle":"Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality","startDateStruct":{"date":"2005-07"},"conditions":["Myelodysplastic Syndromes"],"count":205,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Lenalidomide 5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lenalidomide 5 mg"]},{"label":"Lenalidomide 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lenalidomide 10 mg"]}],"interventions":[{"name":"Lenalidomide 5 mg","otherNames":["Revlimid"]},{"name":"Lenalidomide 10 mg","otherNames":["Revlimid"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must understand and voluntarily sign an informed consent form\n* Age 18 years at the time of signing the informed consent form\n* Documented diagnosis of myelodysplastic syndromes (MDS) that meets International Prognostic Scoring System (IPSS) criteria for low to intermediate-1-risk disease and has an associated del 5q(31) cytogenetic abnormality\n* Red blood cell (RBC) transfusion dependent anaemia defined as not having any 56 days without a RBC transfusion within at least the immediate 112 days\n* Must be able to adhere to the study visit schedule and other protocol requirements\n* Women of childbearing potential must have a negative pregnancy test prior to inclusion\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Prior therapy with lenalidomide\n* Proliferative (white blood cell (WBC)= 12,000/mL) chronic myelomonocytic leukemia (CMML)\n* Prior \\>= grade-2 (using the National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) (v 3.0)) allergic reaction to thalidomide\n* Prior desquamating (blistering) rash while taking thalidomide\n* Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for \\>3 years\n* Use of cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 28 days\n* Less than 6 months since prior allogeneic bone marrow transplantation\n* Less than 3 months since prior autologous bone marrow or stem cell transplantation\n* Less than 28 days since prior myelosuppressive anticancer biologic therapy\n* Recombinant human erythropoietin (rHuEPO) therapy received within 28 days\n* Known human immunodeficiency virus (HIV-1) positivity\n* Any serious medical condition or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he or she participates in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days)","description":"The count of study participants who had no RBC transfusions for 26 consecutive weeks or more during the double-blind period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for 56 Days","description":"Count of study participants who had no RBC transfusions during any 56 or more consecutive study days during the double-blind period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Red Blood Cell (RBC) Transfusion Independence for Participants Who Became RBC Transfusion Independent for at Least 182 Days","description":"Mean number of weeks that participants who achieved RBC transfusion independence for at least 182 days were able to maintain RBC transfusion independence. Both double-blind and open-label periods are included.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":"10.93"},{"groupId":"OG001","value":"107.7","spread":"52.35"},{"groupId":"OG002","value":"108.6","spread":"40.63"}]}]}]},{"type":"SECONDARY","title":"Maximum Change From Baseline in Hemoglobin During the Double-blind Period for Participants Who Became Red Blood Cell (RBC) Transfusion Independent for at Least 182 Days","description":"For participants who became RBC transfusion independent for at least 182 days during the double-blind study period, the mean maximum change from baseline in hemoglobin is summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"0.61"},{"groupId":"OG001","value":"5.5","spread":"1.79"},{"groupId":"OG002","value":"6.0","spread":"1.97"}]}]}]},{"type":"SECONDARY","title":"Participants' Response in Platelet Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period","description":"The International MDS Working Group (IWG) defines a major platelet response for participants with a pre-treatment platelet count of \\<100,000/mm\\^3 as an absolute increase of ≥30,000/mm\\^3 whereas a minor response is defined as a ≥50% increase in platelet count with a net increase greater than 10,000/mm\\^3 but less than 30,000/mm\\^3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants' Response in Absolute Neutrophil Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period","description":"A major neutrophil response is defined by the International MDS Working Group (IWG) criteria as at least a 100% increase, or an absolute increase of ≥500/mm\\^3 for participants with absolute neutrophil counts (ANC) of less than 1,500/mm\\^3 before therapy, whichever is greater. A minor response for such participants is defined as an ANC increase of at least 100%, but absolute increase \\<500/mm\\^3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants' Response Based on Bone Marrow Samples by the International MDS Working Group (IWG 2000) During Double-blind Period","description":"The IWG criteria for bone marrow improvement: a complete remission is bone marrow sampling showing less than 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia. A partial remission is ≥ 50% decrease in blasts over pre-treatment. Bone marrow progression is a ≥ 50% increase in blasts that exceed the top range of the pretreatment percentile range: a) \\<5% blasts b) 5-10% blasts c) 10-20% blasts d) 20-30% blasts. For example, a participant with \\<5% blasts pretreatment with an on study blast increase of 50% which is now \\>5% showed bone marrow progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Showing Cytogenetic Response by the International MDS Working Group (IWG 2000) During Double-blind Period as Evaluated by Central Review","description":"The IWG criteria for evaluating cytogenetic response require a minimum of 20 baseline and post-baseline analyzable metaphases using conventional cytogenetic techniques. A major cytogenetic response is defined as no detectable cytogenetic abnormality if preexisting abnormality was present whereas a minor response requires ≥50% reduction in abnormal metaphases. Progression could be concluded based on as few as 3 metaphases if there were additional abnormalities. The best response is represented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Progressed to Acute Myeloid Leukemia (AML) During the Study","description":"Number of participants who progressed to acute myeloid leukemia during the study, summarized at three different timepoints: first 16 weeks of the double-blind study, week 52 of the double-blind study, and up to 36 months which includes the double-blind and open-label periods of the study. The counts are cumulative by timeframe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan Meier Estimates of Overall Survival by Randomized Group","description":"Kaplan Meier estimate for median length of survival for study participants as they were randomized at the start of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.4","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"44.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Participant Count of Deaths During Double-blind and Open-label by Randomized Group","description":"Count of participant deaths throughout the entire study and reported by the original treatment assignment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12","description":"The Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire (Yellen, 1997) was used to assess health-related quality of life (HRQoL).\n\nIn addition to general HRQoL, the FACT-An measures the impact of fatigue and other anemia-related symptoms on patient functioning. The overall score range for the FACT-An is 0-188. Higher scores indicate better HRQoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"18.50"},{"groupId":"OG001","value":"5.9","spread":"18.26"},{"groupId":"OG002","value":"5.8","spread":"23.17"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Trial Outcome Index-Anemia (TOI-An) Endpoints at Week 12","description":"The Trial Outcome Index-Anemia (TOI-An) composed of the physical and functional subscales of the FACT-G along with the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-An is 0-136. Higher scores indicate better HRQoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"17.13"},{"groupId":"OG001","value":"5.6","spread":"15.56"},{"groupId":"OG002","value":"4.9","spread":"18.16"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Trial Outcome Index-Fatigue (TOI-F) Endpoints at Week 12","description":"The Trial Outcome Index-Fatigue(TOI-F) composed of the physical and functional subscales of the FACT-G along with the fatigue items from the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-F is 0-108. Higher scores indicate better HRQoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"14.76"},{"groupId":"OG001","value":"4.8","spread":"14.21"},{"groupId":"OG002","value":"3.9","spread":"15.47"}]}]}]},{"type":"SECONDARY","title":"Summary of Participants Who Had Adverse Events (AE) During the Double-blind Period","description":"Counts of study participants who had adverse events (AEs) during the double-blind period by MedDRA System Organ Class (SOC) and preferred term. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator.\n\nThe National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":67},"commonTop":["Neutropenia","Diarrhoea","Thrombocytopenia","Constipation","Nausea"]}}}